In this article, Andrew Butcher writes about the importance of stakeholder engagement as effective but high-cost new therapies have potentially damaging financial implications for the healthcare systems expected to fund them. Regrettably, the pharmaceutical industry is often identified as the cause of the problems rather than the key players in solving them.
Rebalancing resources for healthcare and medicines: How much is enough?
This report identifies two key policy objectives that can be generated from healthcare and pharmaceutical spending.